FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3021620214> ?p ?o ?g. }

• W3021620214 abstract "You have accessJournal of UrologyProstate Cancer: Detection & Screening V (PD48)1 Apr 2020PD48-02 DECISION-ANALYTIC MODELING STUDY OF THE PRECISION TRIAL: DOES PRE-BIOPSY MRI DO MORE GOOD THAN HARM? Andrew Vickers* and Sigrid Carlsson Andrew Vickers*Andrew Vickers* More articles by this author and Sigrid CarlssonSigrid Carlsson More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000942.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Several recent studies, including the randomized PRECISION trial, have investigated whether men with elevated prostate-specific antigen (PSA) levels should undergo magnetic resonance imaging (MRI) before prostate biopsy, with targeted biopsy performed if MRI is positive and no biopsy for MRI negative patients. The finding that MRI reduces the number of low-grade and increases the number of high-grade cancers has been interpreted as supporting MRI. However, a technique that overgraded tumors would report similar findings. Study findings at the group level need to be complemented by modeling studies of individual patient counterfactuals. For instance, a patient who would have been grade Grade Group (GG) 1 by regular transrectal ultrasound (TRUS) biopsy but GG2 by MRI would only benefit if confirmatory biopsy after TRUS would show GG2 (hence MRI would avoid an additional biopsy) or if delayed treatment affected chance of cure. If neither are true, the patient would be harmed by curative treatment resulting from the increased grade. METHODS: We used the PRECISION trial results to create different scenarios for individual patient counterfactuals, varying the proportion of MRI-detected high-grade cancers that were reclassified from low-grade vs. benign TRUS biopsy. We assumed that only patients diagnosed with GG2+ would be treated curatively with active surveillance for GG1. We considered treatment to constitute high harm, active surveillance to be moderate harm and additional biopsy to constitute minor harm. As there is evidence that long-term rates of prostate cancer death are very low for both patients with negative TRUS biopsy and those with GG1 followed on active surveillance, delayed treatment was considered to be a moderate harm. We tested a range of scenarios for degree of harm. RESULTS: In most scenarios, MRI was associated with very low levels of net benefit that were highly dependent on assuming that the higher rates of GG2+ disease on MRI resulted from reclassification from benign disease on TRUS. In the base case, the highest net benefit for MRI across scenarios was the equivalent of 50 MRIs to prevent one overdiagnosis of GG1. MRI had was harmful in many scenarios. MRI had important benefit only under the scenario where MRI and TRUS tumors were, grade for grade, of similar oncologic risk, a position not supported by best evidence. CONCLUSIONS: Decision-analytic modelling of how MRI impacts the treatment of individual patients does not support the routine use of MRI before diagnostic biopsy, with biopsy only targeted to suspicious lesions and no biopsy for negative MRI. Source of Funding: This work was supported in part by the National Institutes of Health/National Cancer Institute (NIH/NCI) with a Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center [P30 CA008748], and a SPORE grant in Prostate Cancer [P50-CA92629]. © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e993-e994 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Andrew Vickers* More articles by this author Sigrid Carlsson More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W3021620214 created "2020-05-13" @default.
• W3021620214 creator A5054026380 @default.
• W3021620214 creator A5087481089 @default.
• W3021620214 date "2020-04-01" @default.
• W3021620214 modified "2023-09-27" @default.
• W3021620214 title "PD48-02 DECISION-ANALYTIC MODELING STUDY OF THE PRECISION TRIAL: DOES PRE-BIOPSY MRI DO MORE GOOD THAN HARM?" @default.
• W3021620214 doi "https://doi.org/10.1097/ju.0000000000000942.02" @default.
• W3021620214 hasPublicationYear "2020" @default.
• W3021620214 type Work @default.
• W3021620214 sameAs 3021620214 @default.
• W3021620214 citedByCount "0" @default.
• W3021620214 crossrefType "journal-article" @default.
• W3021620214 hasAuthorship W3021620214A5054026380 @default.
• W3021620214 hasAuthorship W3021620214A5087481089 @default.
• W3021620214 hasBestOaLocation W30216202141 @default.
• W3021620214 hasConcept C121608353 @default.
• W3021620214 hasConcept C126322002 @default.
• W3021620214 hasConcept C126838900 @default.
• W3021620214 hasConcept C143409427 @default.
• W3021620214 hasConcept C2775934546 @default.
• W3021620214 hasConcept C2780192828 @default.
• W3021620214 hasConcept C2781217009 @default.
• W3021620214 hasConcept C71924100 @default.
• W3021620214 hasConceptScore W3021620214C121608353 @default.
• W3021620214 hasConceptScore W3021620214C126322002 @default.
• W3021620214 hasConceptScore W3021620214C126838900 @default.
• W3021620214 hasConceptScore W3021620214C143409427 @default.
• W3021620214 hasConceptScore W3021620214C2775934546 @default.
• W3021620214 hasConceptScore W3021620214C2780192828 @default.
• W3021620214 hasConceptScore W3021620214C2781217009 @default.
• W3021620214 hasConceptScore W3021620214C71924100 @default.
• W3021620214 hasIssue "Supplement 4" @default.
• W3021620214 hasLocation W30216202141 @default.
• W3021620214 hasOpenAccess W3021620214 @default.
• W3021620214 hasPrimaryLocation W30216202141 @default.
• W3021620214 hasRelatedWork W2046981875 @default.
• W3021620214 hasRelatedWork W2094094236 @default.
• W3021620214 hasRelatedWork W2145420319 @default.
• W3021620214 hasRelatedWork W2153860297 @default.
• W3021620214 hasRelatedWork W2157814660 @default.
• W3021620214 hasRelatedWork W2566665866 @default.
• W3021620214 hasRelatedWork W2805225705 @default.
• W3021620214 hasRelatedWork W2964012617 @default.
• W3021620214 hasRelatedWork W3171213747 @default.
• W3021620214 hasRelatedWork W4214538489 @default.
• W3021620214 hasVolume "203" @default.
• W3021620214 isParatext "false" @default.
• W3021620214 isRetracted "false" @default.
• W3021620214 magId "3021620214" @default.
• W3021620214 workType "article" @default.